Treatment

John McCullagh interviews Lisa Power on HIV and aging

published: December, 19, 2012 Written by // John McCullagh - Publisher emeritus Categories // Aging, OHTN OHTN/PositiveLite.com, Conferences, Features and Interviews, Health, Treatment, Living with HIV, Ontario HIV Treatment Network, John McCullagh

What should service providers be doing differently to help people living with HIV stay healthy and active into old age? At the recent OHTN Research Conference in Toronto, John McCullagh put this question to Lisa Power of the UK’s Terrence Higgins Trust

John McCullagh interviews Lisa Power on HIV and aging

Thanks to ART, those of us with HIV are now living much longer. But aging with HIV is not without its challenges. In addition to the normal aging process, people aging with HIV face complications associated with the virus, side effects of treatment and high rates of comorbidities with conditions such as cardiovascular disease, cancer, renal disease, arthritis and osteoporosis. And often we experience social isolation and financial challenges as well.  So what should service providers be

Bob Leahy talks to Patrick Sullivan

published: December, 18, 2012 Written by // Bob Leahy - Publisher Categories // OHTN OHTN/PositiveLite.com, Gay Men, As Prevention , Conferences, Features and Interviews, Health, Sexual Health, Treatment, Ontario HIV Treatment Network, Population Specific , Sex and Sexuality , Bob Leahy - Publisher

What is driving high infection rates in the gay and bi men’s community? And what techniques might work best to address this epidemic within an epidemic? Editor Bob Leahy talks to Patrick Sullivan at the 2012 OHTN Research Conference

Bob Leahy talks to Patrick Sullivan

One of the most interesting sessions at last month’s Ontario HIV Treatment Network (OHTN) 2012 Research Conference in Toronto  was a plenary called “Is Treatment Enough Prevention?” This  session focussed on the recent discourse concerning the potential for antiretroviral therapy to reduce infectiousness and thus, the theory goes, reduce infection rates. But to what extent does treatment as prevention work with gay men?  If it hasn’t worked so far, why not?  And does a discourse

Why it is important to have HIV treatment guidelines

published: December, 16, 2012 Written by // Guest Authors - Revolving Door Categories // Treatment Guidelines -including when to start, Newly Diagnosed, Research, Health, International , Treatment, Revolving Door, Living with HIV, Guest Authors, Population Specific

Canada doesn’t have its own treatment guidelines, so there are no recommended standard treatments or start dates. Is this good? Aidsmap.com details Swiss research which identifies factors associated with the use of non-recommended HIV therapy

Why it is important to have HIV treatment guidelines

This article by Michael Carter first appeared on aidsmap.com here.  New Swiss research shows the importance of observing antiretroviral treatment guidelines, even in people who have well-controlled HIV infection. Published in the online edition of the Journal of Acquired Immune Deficiency Syndromes, the study demonstrated that toxicities and concerns about long-term side-effects were common reasons for switching to recommended treatment. CD4 cell count, viral load and adherence either remain

Infectiousness

published: December, 13, 2012 Written by // Guest Authors - Revolving Door Categories // As Prevention , Health, Research, International , Sexual Health, Treatment, Revolving Door, Living with HIV, Guest Authors

Only half of people on HIV treatment fit 'Swiss Statement' criteria for non-infectiousness in US study, aidsmap.com reports

Infectiousness

This article first appeared on aidsmap.com here. Republished with permission.   A study of a sample of predominantly African-American people with HIV in the US has found that, in those taking antiretroviral therapy (ART), only 51% met the criteria for non-infectiousness set by the Swiss Statement of January 2008. This study (published in HIV Medicine), though small, underlines other findings that African Americans are missing out on the benefits of ART. The high proportion of people with d

Six reasons why people skip their HIV meds

published: December, 13, 2012 Written by // Guest Authors - Revolving Door Categories // Health, Revolving Door, Treatment, Living with HIV, Guest Authors

Never miss a dose we are told, but who hasn’t done it? Here’s Kellee Terrell from TheBody.com with six reasons why we sometimes do it – and what you can do about them

Six reasons why people skip their HIV meds

We all know why it's important to take your HIV medications every day. It keeps the virus in check, keeps you healthy and decreases your chances of becoming resistant to the meds.  But let's face it: For most people, taking HIV medications every day as prescribed isn't the easiest thing to do. And anyone who says otherwise is lying. The reality is that everyday life brings with it obstacles that can block the way between you and your meds. Read on for a quick rundown of some of the common

Half of HIV-positive gay men disagree that HIV treatment makes you less infectious

published: December, 08, 2012 Categories // Gay Men, As Prevention , Research, Health, Sexual Health, Revolving Door, Treatment, Living with HIV, Guest Authors, Population Specific

Maybe they are not well informed, aidsmap.com suggests, but at least they are having safer sex.

Half of HIV-positive gay men disagree that HIV treatment makes you less infectious

This article by Gus Cairns first appeared on aidsmap.com here and is republished with permission.  A survey of over 2000 gay men attending clinics in the UK has found that 48% disagree that HIV treatment can make someone less infectious or makes it unnecessary to use a condom, the eleventh International Congress on Drug Therapy in HIV Infection in Glasgow heard this week. Although the ASTRA (Antiretrovirals, Sexual Transmission Risk and Attitudes) survey found that only 15% of men had rece

Fixing Canada’s Access to Medicines Regime

published: November, 26, 2012 Written by // Guest Authors - Revolving Door Categories // Health, International , Legal, Revolving Door, Treatment, Guest Authors

Canadian HIV/AIDS Legal Network on “What you need to know about Bill C-398”.

Fixing Canada’s Access to Medicines Regime

Canada’s Access to Medicines Regime (CAMR) was a unanimous pledge by Parliament to help people dying in developing countries because they lack access to affordable medicines. So far, it has delivered only one medicine to one country since Parliament created it more than 8 years ago (in May 2004). CAMR is clearly not working; it needs to be reformed to address the unnecessary deficiencies and limitations that have rendered it cumbersome and user-unfriendly for both developing countries and th

Real Life Impact

published: November, 22, 2012 Written by // Bob Leahy - Publisher Categories // OHTN OHTN/PositiveLite.com, Gay Men, As Prevention , Conferences, Features and Interviews, Health, Research, Treatment, Opinion Pieces, Population Specific , Bob Leahy - Publisher

Bob Leahy with a wrap-up report from the OHTN Research Conference – the thrills, the chills and the spills - from an event that promised “Research with Real Life Impact” and delivered.

Real Life Impact

It’s been ten days now, enough time perhaps to process two solidly packed and incredibly busy days in Toronto at the Ontario HIV Treatment Network (OHTN) Research Conference.  But perhaps not enough time. I’m still thinking through some of what I heard, still weighing competing voices, still distilling in my head what I heard.  All of which suggests, I think, the real value and – yes – real life impact of events such as this.  True, the level of our engagement was parti

In search of a level playing field

published: November, 14, 2012 Written by // Guest Authors - Revolving Door, Ontario HIV Treatment Network - Research Categories // OHTN OHTN/PositiveLite.com, Health, Research, Treatment, Revolving Door, Living with HIV, Guest Authors, Ontario HIV Treatment Network

In Canada, is access to HAART/ARV therapy, HIV viral load testing or HIV medical care in general associated with demographic characteristics of people living with HIV? The Ontario HIV Treatment Network (OHTN)’s Rapid Response Unit files their report.

In search of a level playing field

This article first appeared on The Ontario HIV Treatment Network    (OHTN)’s website here. Questions 1. In Canada, is access to HAART/ARV therapy associated with demographic characteristics of PHAs? 2. In Canada, is access to HIV viral load testing, or HIV medical care in keeping with established guidelines and standards, associated with demographic characteristics of PHAs? Key Take-Home Messages . In many Canadian studies, issues related to access to HAART are not addressed becau

Neuropathy and HIV: A Progress Report

published: November, 09, 2012 Categories // Health, Treatment, Living with HIV

Dave R writes...Neuropathy affects up to 40% of all people with HIV, yet the treatment has remained more or less the same for decades. Prescribing drugs meant for other diseases, has led to haphazard results; time for a change - but is it happening?

Neuropathy and HIV: A Progress Report

Couple the conditions neuropathy and HIV-infection together and in 2012, you have more people than ever who understand what you’re talking about. Growing older and surviving with HIV seems to mean the increase of long-term, age or HIV-related, side-effect conditions like neuropathy. To save time in relation to this article; much more information about the disease and its links to HIV can be found in other articles here, here and here. It’s an infuriating and frustrating problem for both

Webinar: HIV and mental health: New thinking, new strategies

published: November, 05, 2012 Categories // Community Events, Events, Mental Health, Research, Health, Events, Revolving Door, Treatment, Living with HIV, Guest Authors

ACT’s third Community Health Forum in the current series is on new thinking and strategies with regard to HIV and mental health. Attendance is free. The forum will also be available as a webinar.

Webinar: HIV and mental health: New thinking, new strategies

The third workshop in the current series of free open discussion forums for people living with HIV hosted by the AIDS Committee of Toronto (ACT) will be held on Wednesday, November 14, 2012 at 7:00 pm at the Ramada Plaza Hotel, 300 Jarvis Street in Toronto.  The topic this month is HIV and mental health: New thinking, new strategies. Topics to be discussed at this forum include:  Mental illness is common in HIV, whether present before infection or as a complication of living with HIV Op

To high-dose or not to high-dose?

published: October, 31, 2012 Written by // Guest Authors - Revolving Door Categories // Alternative Therapies, Food, Nutrition and Recipes, Newly Diagnosed, General Health, Health, Revolving Door, Treatment, Lifestyle, Living with HIV, Guest Authors, Population Specific

From aidsmap.com: High-dose multivitamins have no benefit for people starting HIV treatment but cause serious liver disturbances.

To high-dose or not to high-dose?

This article by Michael Carter first appeared on aidsmap.com here  Republished with permission.  Taking high-dose multivitamins has no health benefits for people starting antiretroviral therapy, but causes serious disturbances in liver function, according to the results of a large randomised trial published in the Journal of the American Medical Association. The study was stopped early after interim results showed that high-dose multivitamins were associated with a more than f

Using Truvada for HIV prevention

published: October, 30, 2012 Categories // As Prevention , Health, Treatment, Opinion Pieces

He's not happy! Danny Miller gives a big no to using Truvada as pre-xposure prophylaxis (PrEP)

So with all the health issues I have had this year I haven’t really had the energy for a good rant in quite a while. But this issue has been nagging at the back of my mind since about mid-summer and I cannot ignore it any longer.  So here goes, hold onto your hats!! This summer, here in the U.S., the FDA (Food and Drug Administration) approved the use of the ARV (anti-retro-viral) drug Truvada as prevention therapy, or PrEP. In short, people who are classified as being in a high risk group

Pill burden and its impact

published: October, 27, 2012 Written by // Guest Authors - Revolving Door Categories // Research, Health, Treatment, Revolving Door, Living with HIV, Guest Authors

Dosing frequency and number of pills don't affect HIV treatment outcomes, reports aidsmap.

Pill burden and its impact

This article by Michael Carter first appeared on aidsmap.com here.  Reproduced with permission.   Levels of adherence to modern HIV treatment are unaffected by dosing frequency or number of daily pills, Italian investigators report in HIV Medicine. However, people who were taking larger numbers of pills reported poorer health. The investigators suggest this is because “many of the patients receiving more complex regimens had more advanced disease and/or were harbouring virus with more dr

AIDS-free generation?

published: October, 25, 2012 Written by // CATIE - HIV and Hep C Info Resource Categories // International AIDS Conference , As Prevention , Conferences, CATIE, Health, International , CATIE - HIV and Hep C Info Resource, Sexual Health, Treatment

CATIE reviews the landscape. "While we are still years away from an ‘AIDS free generation,’ we appear to be on the right path."

AIDS-free generation?

This article first appeared on the website of CATIE  here.   Une version française est disponible ici.  Recent advancements in our understanding of HIV transmission, treatment, prevention and testing are changing the landscape of our response to HIV and generating a significant amount of optimism. The buzz at the International AIDS Conference this past July in Washington D.C. was that we may now be able to achieve an ‘AIDS-free generation’ where first, no one will be born with the vi

<<  39 40 41 42 43 [4445 46 47 48  >>